Perceived influence of alcohol consumption, substance use, and mental health on PrEP adherence and condom use among PrEP-prescribed gay, bisexual, and other men-who-have-sex-with-men: a qualitative investigation.
Adherence
Alcohol
Gay/Bisexual/MSM
HIV Pre-Exposure Prophylaxis (PrEP)
Mental Health
Substance Use
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
07 10 2022
07 10 2022
Historique:
received:
21
07
2022
accepted:
30
09
2022
entrez:
7
10
2022
pubmed:
8
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
Gay, bisexual, and other men-who-have-sex-with-men (GBMSM) continue to be disproportionately affected by Human Immunodeficiency Virus (HIV). Although HIV pre-exposure prophylaxis (PrEP) offers an effective means of reducing incident HIV among this population, the HIV-preventive success of oral-based PrEP is contingent upon regimen adherence. Elevated rates of alcohol-, substance use-, and mental health-related issues among GBMSM potentially hinder PrEP-taking efforts, however the evidence for this remains mixed. Accordingly, the present study entailed a comprehensive qualitative investigation to explore PrEP-prescribed GBMSM's perceptions surrounding the influence of alcohol, substance use, and mental health on PrEP adherence. PrEP-prescribed GBMSM (age ≥ 18 years; prescribed PrEP for ≥ 3 months) were recruited from two PrEP-delivery clinics in Toronto, Canada for focus groups as part of the formative phase of an alcohol-, substance use-, and mental health-focused randomized controlled intervention trial. Focus group discussions qualitatively explored perceived strengths and barriers associated with adherence to PrEP treatment; with an emphasis on alcohol, substance use, and mental health concerns. Condom use among PrEP-prescribed GBMSM within the context of these concerns was also discussed. A total of five focus groups involving 35 GBMSM were conducted (4-10/group; mean age = 42.4; white = 71.4%). Although participants themselves generally reported successfully adhering to their PrEP regimens-resulting from a strong, underlying motivation for self-care-they recognized the detrimental impact that alcohol, substance use, and mental health had on adherence among their peers. In this regard, alcohol and substances were perceived as detracting from adherence only when consumption was excessive or temporally linked to PrEP dosing. Pronounced mental health issues (e.g., severe depression) were also seen as hindering adherence, although these effects were nuanced and perceived as person-dependent. Alcohol and substances were linked to condomless sex, regardless of PrEP use, and PrEP was therefore viewed as an HIV-protective 'safety net.' Overall, findings suggest that PrEP adherence can often be successfully achieved in the presence of alcohol-, substance use-, and mental health-related issues. Augmenting self-care, and addressing pronounced addictions- and mental health-related concerns, may enhance PrEP treatment among GBMSM.
Sections du résumé
BACKGROUND
Gay, bisexual, and other men-who-have-sex-with-men (GBMSM) continue to be disproportionately affected by Human Immunodeficiency Virus (HIV). Although HIV pre-exposure prophylaxis (PrEP) offers an effective means of reducing incident HIV among this population, the HIV-preventive success of oral-based PrEP is contingent upon regimen adherence. Elevated rates of alcohol-, substance use-, and mental health-related issues among GBMSM potentially hinder PrEP-taking efforts, however the evidence for this remains mixed. Accordingly, the present study entailed a comprehensive qualitative investigation to explore PrEP-prescribed GBMSM's perceptions surrounding the influence of alcohol, substance use, and mental health on PrEP adherence.
METHODS
PrEP-prescribed GBMSM (age ≥ 18 years; prescribed PrEP for ≥ 3 months) were recruited from two PrEP-delivery clinics in Toronto, Canada for focus groups as part of the formative phase of an alcohol-, substance use-, and mental health-focused randomized controlled intervention trial. Focus group discussions qualitatively explored perceived strengths and barriers associated with adherence to PrEP treatment; with an emphasis on alcohol, substance use, and mental health concerns. Condom use among PrEP-prescribed GBMSM within the context of these concerns was also discussed.
RESULTS
A total of five focus groups involving 35 GBMSM were conducted (4-10/group; mean age = 42.4; white = 71.4%). Although participants themselves generally reported successfully adhering to their PrEP regimens-resulting from a strong, underlying motivation for self-care-they recognized the detrimental impact that alcohol, substance use, and mental health had on adherence among their peers. In this regard, alcohol and substances were perceived as detracting from adherence only when consumption was excessive or temporally linked to PrEP dosing. Pronounced mental health issues (e.g., severe depression) were also seen as hindering adherence, although these effects were nuanced and perceived as person-dependent. Alcohol and substances were linked to condomless sex, regardless of PrEP use, and PrEP was therefore viewed as an HIV-protective 'safety net.'
CONCLUSIONS
Overall, findings suggest that PrEP adherence can often be successfully achieved in the presence of alcohol-, substance use-, and mental health-related issues. Augmenting self-care, and addressing pronounced addictions- and mental health-related concerns, may enhance PrEP treatment among GBMSM.
Identifiants
pubmed: 36207757
doi: 10.1186/s12889-022-14279-2
pii: 10.1186/s12889-022-14279-2
pmc: PMC9540691
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1875Subventions
Organisme : NIAAA NIH HHS
ID : UH2 AA026212
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
N Engl J Med. 2015 Feb 5;372(6):509-18
pubmed: 25651245
Clin Infect Dis. 2015 Nov 15;61(10):1601-3
pubmed: 26334052
Ann Behav Med. 2014 Jun;47(3):259-69
pubmed: 24234601
AIDS Behav. 2013 Jul;17(6):2162-72
pubmed: 23080358
J Infect Dis. 2018 Oct 5;218(10):1551-1559
pubmed: 30295803
AIDS Behav. 2016 Jul;20(7):1478-88
pubmed: 26078115
J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):180-202
pubmed: 19668086
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
AIDS Patient Care STDS. 2014 Dec;28(12):666-76
pubmed: 25329778
PLoS One. 2011;6(11):e27533
pubmed: 22140446
AIDS. 2015 Jul 17;29(11):1277-85
pubmed: 26103095
Ann Behav Med. 2011 Feb;41(1):83-91
pubmed: 20922510
BMC Public Health. 2020 Nov 25;20(1):1782
pubmed: 33256651
J Int AIDS Soc. 2018 Mar;21(3):e25103
pubmed: 29577616
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
AIDS Behav. 2020 Dec;24(12):3436-3455
pubmed: 32385678
Int J Nurs Stud. 2012 Mar;49(3):360-71
pubmed: 21996649
AIDS Care. 2021 Jun;33(6):697-705
pubmed: 32530302
AIDS Educ Prev. 2020 Oct;32(5):416-431
pubmed: 33112675
Can Commun Dis Rep. 2019 Dec 05;45(12):304-312
pubmed: 32167090
AIDS Behav. 2009 Aug;13(4):757-82
pubmed: 18236149
PLoS Med. 2013;10(9):e1001511
pubmed: 24058300
AIDS Care. 2009 Oct;21(10):1321-34
pubmed: 20024709
Clin Infect Dis. 2014 Jul;59 Suppl 1:S55-60
pubmed: 24926036
Psychol Bull. 2009 Sep;135(5):707-730
pubmed: 19702379
AIDS Behav. 2016 Jul;20(7):1461-9
pubmed: 25835463
AIDS Behav. 2015 May;19(5):794-801
pubmed: 25432877
J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):e94-e98
pubmed: 31192894
Int J Drug Policy. 2022 May;103:103630
pubmed: 35231668
PLoS One. 2018 Dec 26;13(12):e0205919
pubmed: 30586354
Sci Transl Med. 2012 Sep 12;4(151):151ra125
pubmed: 22972843
AIDS Care. 2018 Feb;30(2):191-198
pubmed: 28830220
Health Psychol. 2004 Sep;23(5):525-32
pubmed: 15367072
J Int AIDS Soc. 2020 Apr;23(4):e25472
pubmed: 32294338
N Engl J Med. 2021 Aug 12;385(7):595-608
pubmed: 34379922
Alcohol Clin Exp Res. 2015 Feb;39(2):380-9
pubmed: 25684055
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
Drug Alcohol Depend. 2021 Sep 1;226:108875
pubmed: 34218004
Drug Alcohol Depend. 2015 Mar 1;148:69-76
pubmed: 25596785
Health Psychol. 2008 Sep;27(5):628-37
pubmed: 18823189
J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):e18-e26
pubmed: 31490342
AIDS Behav. 2017 Nov;21(Suppl 2):126-143
pubmed: 28831609
J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):149-158
pubmed: 31335588
AIDS Behav. 2019 May;23(5):1277-1286
pubmed: 30306433
J Assoc Nurses AIDS Care. 2004 Jul-Aug;15(4):58-67
pubmed: 15296659
Prev Sci. 2017 Aug;18(6):737-747
pubmed: 28578516
AIDS Behav. 2020 Jun;24(6):1727-1742
pubmed: 31673913
Front Pharmacol. 2019 Jul 12;10:785
pubmed: 31354496
Clin Infect Dis. 2020 Oct 23;71(7):e135-e140
pubmed: 31677383
Int J Drug Policy. 2019 Dec;74:246-254
pubmed: 31739177
Drug Alcohol Rev. 2015 Jul;34(4):349-57
pubmed: 25546071
J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):271-279
pubmed: 28328548
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037